Effects of isradipine or enalapril on blood pressure in salt-sensitive hypertensives during low and high dietary salt intake. MIST II Trial Investigators
- PMID: 11078178
- DOI: 10.1016/s0895-7061(00)01183-3
Effects of isradipine or enalapril on blood pressure in salt-sensitive hypertensives during low and high dietary salt intake. MIST II Trial Investigators
Abstract
This large multicenter study, tested the antihypertensive effects of isradipine, a dihydropyridine calcium channel blocker and enalapril, an angiotensin-converting enzyme inhibitor, in salt-sensitive hypertensive patients under low and high salt intake diets. After a 3-week (weeks -9 to -6) of ad lib salt diet, those patients who had a sitting diastolic blood pressure (SDBP) of > or =95 but < or =115 mm Hg qualified to enter a 3-week (weeks -6 to -3) placebo run-in low salt diet (50 to 80 mmol Na+/day). Then high salt (200 to 250 mmol Na+/day) was added to the placebo treatment for 3 weeks (weeks -3 to 0). Those patients who demonstrated an increase in SDBP > or =5 mm Hg from the low to high salt diet were considered salt sensitive and were randomized into a 4-week (weeks 0 to 4) double-blind treatment period of either isradipine 2.5 to 10 mg twice a day, enalapril 2.5 to 20 mg twice a day, or placebo. Then they entered a 3-week (weeks 4 to 7) placebo washout phase of low salt diet (50 to 80 mmol Na+/day). After week 7 and while the low salt diet was continued the patients were restarted on their double-blind treatment for 4 more weeks (weeks 7 to 11) and the study was completed. Of 1,916 patients screened, 464 were randomized into the double-blind treatment phase and 397 completed the study. Both isradipine and enalapril decreased the sitting systolic blood pressure (SSBP) and SDBP during the high salt diet, to a similar degree, whereas enalapril caused a greater reduction in SSBP and SDBP than isradipine during the low salt diet (11.3 +/- 1.2/7.7 +/- 0.7 mm Hg v 7.7 +/- 0.9/4.8 +/- 0.6 mm Hg, mean +/- SEM, respectively, P < .02). Within drugs, the effect of isradipine on blood pressure (BP) was higher during the high than the low salt diet (14.9 +/- 1.5 v 7.6 +/- 1.3 mm Hg for SSBP and 10.1 +/- 0.6 v 4.8 +/- 0.9 mm Hg for SDBP, P < .001), but enalapril exerted a similar effect during both diets. Because salt restriction lowered both SSBP and SDBP, the lowest BP achieved with both drugs were during the salt restriction phase.
Similar articles
-
Influence of race and dietary salt on the antihypertensive efficacy of an angiotensin-converting enzyme inhibitor or a calcium channel antagonist in salt-sensitive hypertensives.Hypertension. 1998 May;31(5):1088-96. doi: 10.1161/01.hyp.31.5.1088. Hypertension. 1998. PMID: 9576119 Clinical Trial.
-
Salt and blood pressure responses to calcium antagonism in hypertensive patients.Hypertension. 1997 Sep;30(3 Pt 1):422-7. doi: 10.1161/01.hyp.30.3.422. Hypertension. 1997. PMID: 9314427 Clinical Trial.
-
Fosinopril versus enalapril in the treatment of hypertension: a double-blind study in 195 patients.J Cardiovasc Pharmacol. 1996 Jul;28(1):1-5. doi: 10.1097/00005344-199607000-00001. J Cardiovasc Pharmacol. 1996. PMID: 8797128 Clinical Trial.
-
Hypertension's 3 Dilemmas and 3 Solutions: Pharmacology of the Kidney in Hypertension.J Cardiovasc Pharmacol. 2017 Mar;69(3):129-139. doi: 10.1097/FJC.0000000000000458. J Cardiovasc Pharmacol. 2017. PMID: 28267687 Free PMC article. Review.
-
Review of salt restriction and the response to antihypertensive drugs. Satellite symposium on calcium antagonists.Hypertension. 1988 Feb;11(2 Pt 2):I229-32. doi: 10.1161/01.hyp.11.2_pt_2.i229. Hypertension. 1988. PMID: 2894358 Review.
Cited by
-
Effect of longer-term modest salt reduction on blood pressure.Cochrane Database Syst Rev. 2013 Apr 30;2013(4):CD004937. doi: 10.1002/14651858.CD004937.pub2. Cochrane Database Syst Rev. 2013. PMID: 23633321 Free PMC article.
-
Rationale for combination therapy as initial treatment for hypertension.J Clin Hypertens (Greenwich). 2003 Jul-Aug;5(4 Suppl 3):4-11. doi: 10.1111/j.1524-6175.2003.02673.x. J Clin Hypertens (Greenwich). 2003. PMID: 12941992 Free PMC article. Review.
-
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Major outomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic.Curr Hypertens Rep. 2003 Jun;5(3):189-91. doi: 10.1007/s11906-003-0019-8. Curr Hypertens Rep. 2003. PMID: 12724049 No abstract available.
-
Has the role of calcium channel blockers in treating hypertension finally been defined?Curr Hypertens Rep. 2003 Aug;5(4):295-300. doi: 10.1007/s11906-003-0037-6. Curr Hypertens Rep. 2003. PMID: 12844463 Review.
-
Dietary salt restriction and blood pressure in clinical trials.Curr Hypertens Rep. 2007 Aug;9(4):314-9. doi: 10.1007/s11906-007-0057-8. Curr Hypertens Rep. 2007. PMID: 17686383 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous